Schachtner, Thomas <br/><br/>
Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.  [electronic resource] 

 -  Transplant infectious disease : an official journal of the Transplantation Society  Dec 2016 
 - 881-888 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1399-3062 
<br/><br/><label>Standard No.: </label>10.1111/tid.12605  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Allografts--drug effects<br/>B-Lymphocytes--drug effects<br/>Epstein-Barr Virus Infections--blood<br/>Female<br/>Follow-Up Studies<br/>Graft Rejection--epidemiology<br/>Herpesvirus 4, Human--drug effects<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Kidney Transplantation--adverse effects<br/>Lymphoproliferative Disorders--etiology<br/>Male<br/>Middle Aged<br/>Pilot Projects<br/>Retrospective Studies<br/>Rituximab--administration & dosage<br/>Serologic Tests<br/>Tissue Donors<br/>Transplant Recipients<br/>Transplantation Conditioning--methods<br/>Viremia--prevention & control<br/>Young Adult